

**PB 135 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024

I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 28 November 2024

Eden Simon

Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 December 2024 2

National Health (Minimum Stockholding) Determination 2023 2

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024*.

 (2) This instrument may also be cited as PB 135 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 December 2024. | 1 December 2024 |
| 2. Schedule 1 | 1 December 2024. | 1 December 2024 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 December 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aciclovir | Tablet 200 mg | Oral | Aciclovir APOTEX | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |
| Aciclovir | Tablet 200 mg | Oral | ARX-ACICLOVIR | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |
| Aciclovir | Tablet 800 mg | Oral | Aciclovir APOTEX | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |
| Aciclovir | Tablet 800 mg | Oral | ARX-ACICLOVIR | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Allopurinol | Tablet 100 mg | Oral | Allosig | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Allopurinol | Tablet 100 mg | Oral | APO-ALLOPURINOL | 4 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Allopurinol | Tablet 100 mg | Oral | Zyloprim | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Allopurinol | Tablet 300 mg | Oral | APO-ALLOPURINOL | 6 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together |

4 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand(b) after 31 December 2023—4.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amlodipine | Tablet 5 mg (as besilate) | Oral | APX-AMLODIPINE | 6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together |

5 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Azacitidine | Powder for injection 100 mg | Injection | Azacitidine-Teva | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |

6 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | Cipla Bisoprolol | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | Bivalirudin APOTEX | 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together |
| Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | BIVALIRUDIN ARX | 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together |

7 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefazolin | Powder for injection 1 g (as sodium) | Injection | Cefazolin-AFT | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Cefepime Kabi | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |
| Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime Kabi | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |

9 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Capsule 100 mg | Oral | APO‑Ciclosporin | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Capsule 100 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |

10 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Capsule 25 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Capsule 25 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |

11 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Capsule 50 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Capsule 50 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |

12 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)-100 mg | Oral | Clopidogrel Winthrop plus aspirin | between 1 December 2024 and 31 March 2025—0 months stock by reference to usual demand |

13 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Entecavir Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | Entecavir Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

14 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Epoprostenol | Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL | Injection | Flolan | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |
| Epoprostenol | Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL | Injection | Flolan | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |

15 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluconazole | Capsule 200 mg | Oral | APO-Fluconazole | 4 months stock by reference to usual demand of both Fluconazole APOTEX and APO-Fluconazole added together |

16 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Furosemide | Oral solution 10 mg per ml, 30 ml | Oral | Lasix | (a) between 1 November 2024 and 31 March 2024—4 months stock by reference to usual PBS demand(b) after 31 March 2024—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Furosemide | Oral solution 10 mg per ml, 30 ml | Oral | Lasix | (a) between 1 November 2024 and 31 March 2025—4 months stock by reference to usual PBS demand(b) after 31 March 2025—6 months stock by reference to usual PBS demand |

17 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gabapentin | Capsule 400 mg | Oral | GAPENTIN | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gabapentin | Tablet 600 mg | Oral | APX-GABAPENTIN | 4 months stock by reference to usual demand of both Gabapentin APOTEX and APX-GABAPENTIN added together |

18 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glimepiride | Tablet 1 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 1 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 2 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 2 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 3 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 3 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 4 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 4 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |

19 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand |

20 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the Eye | HPMC PAA | between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib-APOTEX | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib-APOTEX | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |

21 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | AVSARTAN HCT 150/12.5 | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Iron polymaltose complex | Injection 100 mg (iron) in 2 mL | Injection | Ferrosig | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |

22 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost/Timolol 0.05/5 | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Leflunomide | Tablet 10 mg | Oral | APO-LEFLUNOMIDE | 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together |
| Leflunomide | Tablet 20 mg | Oral | APO-LEFLUNOMIDE | 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together |
| Letrozole | Tablet 2.5 mg | Oral | ARX-LETROZOLE | 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together |
| Letrozole | Tablet 2.5 mg | Oral | Letrozole APOTEX | 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together |

23 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Milk protein and fat formula with vitamins and minerals -- carbohydrate free | Oral powder 225 g (Carbohydrate Free Mixture) | Oral | Carbohydrate Free Mixture | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mirtazapine | Tablet 45 mg | Oral | NOUMED MIRTAZAPINE | between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand |

24 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Modafinil | Tablet 100 mg | Oral | Modafin | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Modafinil | Tablet 100 mg | Oral | Modafinil Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together |
| Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | APX-Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together |
| Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | APX-Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | ARX-MYCOPHENOLATE | 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Mycophenolate APOTEX | 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together |

25 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nortriptyline | Tablet 25 mg (as hydrochloride) | Oral | NortriTABS 25 mg | between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 10 mg | Oral | APO-OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |

26 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together. |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 2.5 mg | Oral | APO-OLANZAPINE | 6 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |

27 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg | Oral | APO-OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |

28 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 7.5 mg | Oral | APO-OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |

29 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand(b) after 31 December 2023—3.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 20/5 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 20/5 mg added together |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 40/10 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/10 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/10 added together |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 40/5 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/5 mg added together |

30 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together |

31 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO‑Pantoprazole | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand(b) after 31 December 2023—5.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together |

32 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Phenoxymethylpenicillin | Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL | Oral | Phenoxymethylpenicillin-AFT | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |

33 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pimecrolimus | Cream 10 mg per g, 15 g | Application | Elidel | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |

34 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Protein hydrolysate formula with medium chain triglycerides | Oral powder 450 g (Aptamil Gold+ Pepti-Junior) | Oral | Aptamil Gold+ Pepti-Junior | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Quetiapine | Tablet 100 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |
| Quetiapine | Tablet 200 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |
| Quetiapine | Tablet 25 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |
| Quetiapine | Tablet 300 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |

35 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | APO-RIZATRIPTAN ODT | 4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO-RIZATRIPTAN ODT added together |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APO-Rosuvastatin | 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-Rosuvastatin added together |
| Rosuvastatin | Tablet 20 mg (as calcium) | Oral | APO-ROSUVASTATIN | 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together |
| Rosuvastatin | Tablet 40 mg (as calcium) | Oral | APO-ROSUVASTATIN | 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APO-ROSUVASTATIN | 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together |

36 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 ml single dose units, 30 | Inhalation | Salbutamol Cipla | between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand. |
| Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30 | Inhalation | Salbutamol Cipla | between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand. |

37 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | ARX-SEVELAMER | 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | Sevelamer Apotex | 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together |

38 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Telmisartan | Tablet 40 mg | Oral | NOUMED TELMISARTAN | between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand |

39 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Temazepam | Tablet 10 mg | Oral | APO‑Temazepam | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir APOTEX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir ARX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |

40 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand |

41 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 ARX | 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together |

42 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valproic acid | Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Syrup | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | APO-Sodium Valproate | between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Epilim EC | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Sodium Valproate Sandoz | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valprease 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valpro EC 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valproate Winthrop EC 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | APO-Sodium Valproate | between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Epilim EC | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Sodium Valproate Sandoz | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valprease 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valpro EC 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valproate Winthrop EC 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |

43 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |

44 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |